916738-12-0

Basic information

• Product Name: 2-chloro-5-fluoro-N₄-[4-(prop-2-ynyloxy)phenyl]-4-pyrimidineamine
• Synonyms: 2-chloro-5-fluoro-N₄-[4-(prop-2-ynyloxy)phenyl]-4-pyrimidineamine
• CAS NO: 916738-12-0
• Molecular Weight: 277.685
• Mol File: 916738-12-0.mol

Chemical Properties

• Boiling Point: 447.8±45.0 °C(Predicted)
• Density: 1.396±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-chloro-5-fluoro-N₄-[4-(prop-2-ynyloxy)phenyl]-4-pyrimidineamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-fluoro-N₄-[4-(prop-2-ynyloxy)phenyl]-4-pyrimidineamine(916738-12-0)
• EPA Substance Registry System: 2-chloro-5-fluoro-N₄-[4-(prop-2-ynyloxy)phenyl]-4-pyrimidineamine(916738-12-0)

Safety Data

• Hazardous Substances Data: 916738-12-0(Hazardous Substances Data)

Upstream product

• 17061-85-7 1-nitro-4-(prop-2-ynyloxy)benzene 
• 26557-78-8 4-(prop-2-ynyloxy)aniline 
• 2927-71-1 2,4-dichloro-5-fluoropyrimidine 

Relevant articles and documents

COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME

Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a kinase inhibitor, such as a JAK inhibitor and/or an IRAK inhibitor, and/or the compound may have a structure according to Formulas I, III, IV or VII. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.

2,4 SUBSTITUTED PYRIMIDINEDIAMINES FOR USE IN DISCOID LUPUS

no abstract published

TREATMENT FOR VITILIGO

Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions.

COMPOSITION FOR OPHTHALMIC ADMINISTRATION

Disclosed herein are embodiments of a composition useful for treating and/or preventing dry eye disorders. The disclosed composition comprises components that maintain the composition's chemical and/or physical properties thereby providing a composition suitable for use.

COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY

Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the eye.